share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  05/15 17:11
Moomoo AI 已提取核心信息
180 Life Sciences Corp. has failed to meet the Nasdaq's minimum stockholders' equity requirement and faces potential delisting. The company was previously notified by Nasdaq on November 15, 2023, of its non-compliance with the $2.5 million equity threshold. Despite submitting a compliance plan and being granted an extension until May 13, 2024, 180 Life Sciences was unable to complete the necessary transactions to meet the requirement. Consequently, on May 14, 2024, Nasdaq issued a delisting determination letter to the company. 180 Life Sciences plans to request a hearing with the Nasdaq Hearings Panel in an attempt to present a new compliance plan and delay delisting. Trading of the company's common stock, under the symbol 'ATNF', will continue on Nasdaq pending the hearing's outcome. Additionally, on the...Show More
180 Life Sciences Corp. has failed to meet the Nasdaq's minimum stockholders' equity requirement and faces potential delisting. The company was previously notified by Nasdaq on November 15, 2023, of its non-compliance with the $2.5 million equity threshold. Despite submitting a compliance plan and being granted an extension until May 13, 2024, 180 Life Sciences was unable to complete the necessary transactions to meet the requirement. Consequently, on May 14, 2024, Nasdaq issued a delisting determination letter to the company. 180 Life Sciences plans to request a hearing with the Nasdaq Hearings Panel in an attempt to present a new compliance plan and delay delisting. Trading of the company's common stock, under the symbol 'ATNF', will continue on Nasdaq pending the hearing's outcome. Additionally, on the same day, the company was notified of non-compliance with Nasdaq's audit committee requirements, which mandates at least three independent directors. The company is seeking to address this issue and expects to regain compliance soon. The potential delisting could significantly impact the company's stock and warrant prices and its ability to raise capital.
180 Life Sciences Corp. 未能达到纳斯达克的最低股东权益要求,可能面临退市风险。纳斯达克此前曾于2023年11月15日通知该公司,称其未遵守250万美元的股权门槛。尽管提交了合规计划并获准延期至2024年5月13日,但180 Life Sciences仍无法完成必要的交易以满足要求。因此,纳斯达克于2024年5月14日向该公司发布了退市决定函。180生命科学计划要求纳斯达克听证会小组举行听证会,试图提出新的合规计划并推迟退市。在听证会得出结果之前,股票代码为 “ATNF” 的公司普通股将继续在纳斯达克交易。此外,该公司在同一天被告知不遵守纳斯达克审计委员会的要求,该要求要求至少有三名独立董事。该公司正在寻求解决这个问题,并预计将很快恢复合规。潜在的退市可能会对公司的股票和认股权证价格及其筹集资金的能力产生重大影响。
180 Life Sciences Corp. 未能达到纳斯达克的最低股东权益要求,可能面临退市风险。纳斯达克此前曾于2023年11月15日通知该公司,称其未遵守250万美元的股权门槛。尽管提交了合规计划并获准延期至2024年5月13日,但180 Life Sciences仍无法完成必要的交易以满足要求。因此,纳斯达克于2024年5月14日向该公司发布了退市决定函。180生命科学计划要求纳斯达克听证会小组举行听证会,试图提出新的合规计划并推迟退市。在听证会得出结果之前,股票代码为 “ATNF” 的公司普通股将继续在纳斯达克交易。此外,该公司在同一天被告知不遵守纳斯达克审计委员会的要求,该要求要求至少有三名独立董事。该公司正在寻求解决这个问题,并预计将很快恢复合规。潜在的退市可能会对公司的股票和认股权证价格及其筹集资金的能力产生重大影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息